FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL					
OMB Number:	3235-028					
Estimated average burden						
hours per response	0					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)															
1. Name and Address of Reporting Person* KUMAR AMIT				2. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director 10% Owner				
(Last) (First) (Middle) C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250				3. Date of Earliest Transaction (Month/Day/Year) 03/10/2022							X	X Officer (give title below) Other (specify below) Chief Executive Officer				
(Street) SAN JOSE., CA 95118				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X. Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City)		(State)	(Zip)			7	able I	- Non-D	erivativ	ve Securitie	s Acquired	, Disposed o	f, or Benefi	cially Owned		
1.Title of Sec (Instr. 3)	curity		2. Transaction Date (Month/Day/Year) any	tion l	Date, if			(A) or	Disposed of 3, 4 and 5) (A) or nt (D)	f (D) Own	mount of Second Followin neaction(s) tr. 3 and 4)		C F I C	Ownership orm: B Oirect (D) C r Indirect (I	Nature f Indirect eneficial twnership instr. 4)
			Table II					in this a curi	s form rently posed		equired to control n	respond ur umber.		on contained orm display		174 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	ction	5. Numb	er of ve es d (A) sed of	6. Date I Expiration (Month/	Exercisson Date Day/Ye	able and e ear)	7. Title an of Underly Securities (Instr. 3 an	ring		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
Employee Stock Option (Right to Buy)	\$ 2.74	03/10/2022		Code	V	(A) 500,00	(D)			3/10/2032	Commo: Stock	of Shares	\$ 0	500,000	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director 10% Owner Officer		Officer	Other		
KUMAR AMIT C/O ANIXA BIOSCIENCES, INC. 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE,, CA 95118	X		Chief Executive Officer			

Signatures

/s/ Amit Kumar	03/11/2022			
**Signature of Reporting Person	Date			

Explanation of Responses:

- \star If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
- (2) The options vest and become exercisable in thirty-six (36) equal monthly installments beginning March 31, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.